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Abstract
Background: The low survival rate of hepatocellular carcinoma (HCC) is partly attributable to its resistance to
existing chemotherapeutic agents. Until now, there have been limited chemotherapeutic agents for liver cancer.
Epithelial cell adhesion molecule (EpCAM) has been found to be over-expressed during stages of carcinogenesis
and has been associated with poor overall survival in many cancers. The aim of this study was to evaluate EpCAM
expression in HCC and evaluate the effects of EpCAM to established chemotherapy.
Methods: Three human hepatocellular carcinoma cell lines—HepG2, Hep3B and HuH-7—were pre- and post-
treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin. Cell viability and EpCAM protein expression were
measured by MTT assay and Western Blotting respectively. EpCAM positive cells were analyzed by flow
cytometry. To evaluate the effects of doxorubicin efficacy on EpCAM positive cells, a small interfering RNA
(siRNA) specific to EpCAM was transfected into the cells and treated with doxorubicin. Results: EpCAM was
significantly down-regulated by doxorubicin treatment in all three HCC cell lines (P <0.05 or 0.01). EpCAM
expression was down-regulated by the 5-FU and cisplatin in HepG2 cells, however the EpCAM expression was
up-regulated by 5-FU and cisplatin in Hep3B cell line. EpCAM expression was down-regulated by 5-FU, and
up-regulated by cisplatin in Huh-7 cell line. Flow cytometry assay showed doxorubicin exposure decreased
EpCAM positive cell quantities in three HCC cell lines. EpCAM siRNA knock-down attenuated cell mortality
after doxorubicin exposure.
Conclusion: All of these findings demonstrate that EpCAM is one of targets of chemoresistence.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related mortality worldwide [1]. It
is the most common type of liver cancer. The 5-year sur-
vival rate of liver cancer patients in the United States is
very low; it is the second most lethal cancer after pan-
creatic ductal adenocarcinoma [2]. The low survival rate
of liver cancer partly comes from its resistance to exist-
ing chemotherapeutic agents [3]. At this time, there are
no perfect anticancer chemotherapeutic agents for liver
cancer.
5-fluorouracil (5-FU), cisplatin and doxorubicin are
commonly used therapeutic agents in the clinical setting.
The fluoropyrimidine 5-FU is an antimetabolite drug that
is widely used for the treatment of cancer, particularly for
colorectal cancer. It works through noncompetitive inhib-
ition of thymidylate synthase and incorporation of its me-
tabolites into RNA and DNA [4]. Inside the cell, 5-FU is
transformed into different cytotoxic metabolites and in-
duces cell cycle arrest and apoptosis by blocking the cell’s
ability to synthesize DNA. Specifically, 5-FU interferes
with the synthesis of deoxythymidylate (dTMP). Without
dTMP, rapidly dividing cancerous cells were induced into
thymineless death. In addition, 5-FU has been reported to
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inhibit the activity of the exosome complex, which is es-
sential for cell rRNA processing [5].
Cisplatin is a platinum-based chemotherapy drug used
to treat various types of cancers. Inside a cell, cisplatin
forms a platinum complex that binds to and cross-links
DNA. This cross-linking damages DNA and repair mech-
anisms are activated. Once the repair mechanisms dam-
aged, the cells are found to not be salvageable, the death
of those cells is triggered through apoptosis.
The exact mechanism of action of doxorubicin is com-
plex and still somewhat unclear, though it is thought to
interact with DNA by intercalation [6] and inhibition of
macromolecular biosynthesis [7]. In our research, we
found that doxorubicin can down-regulate epithelial cell
adhesion molecule (EpCAM) expression and decrease
EpCAM-positive cell amounts in human HCC cell lines.
EpCAM is an epithelium-specific, Ca2+ independent,
cell-to-cell adhesion molecule. It is encoded by the
EPCAM gene in humans and also has been designated
as TACSTD1 (tumor-associated calcium signal trans-
ducer one).
EpCAM is expressed in fetal lung, kidney, liver, pan-
creas, skin, and germ cells, and in adult epithelia. EpCAM
up-regulates the proto-oncogene c-Myc and cyclins A/E,
which are involved in the cell cycle and proliferation.
EpCAM over-expression is correlated with cancer malig-
nancy and with poor survival in breast [8], ovarian [9],
colon, esophageal squamous cell carcinoma [10] and squa-
mous head and neck carcinoma cells. The function of
EpCAM and its regulatory mechanism are largely unclear
in HCC. Our research results showed that EpCAM is the
target of doxorubicin, which can down-regulate levels of
EpCAM expression and EpCAM-positive cells in HCC
cell lines HepG2, Hep3B and HuH-7.
Methods
This study involved the use of three human HCC cell
lines—HepG2, Hep3B and HuH-7—which were used in
accordance with the Helsinki Declaration. No human
subjects were used in these studies.
Cell culture
Hep3B and HepG2 cells were obtained from American
Type Culture Collection (Rockville, MD). HuH-7 cells
were purchased from Invitrogen Company (Carlsbad,
CA). HepG2 and HuH-7 were grown in Dulbecco’s
Modified Eagle Medium (DMEM, Invitrogen, Carlsbad,
CA) supplemented with 10 % fetal bovine serum and
penicillin (100 U/ml)/streptomycin sulfate (100 μg/ml)
(Invitrogen, Carlsbad, CA). Hep3B was grown in Eagle’s
Minimum Essential Medium (EMEM, Invitrogen, Carls-
bad, CA) supplemented with 10 % fetal bovine serum
and penicillin (100 U/ml)/streptomycin sulfate (100 μg/
ml) (Invitrogen, Carlsbad, CA).
MTT assay
Cell viability was measured by MTT assay. In order to
reduce the influence of the chemotherapeutic reagent on
MTT results, we set up blank controls for each different
concentration of chemotherapeutic agents. Cells were
plated on 96-well plates at a density of 1 × 104 cells per
well. When 90 % growing confluent reached, cells were
assigned to three groups and treated with different con-
centrations of doxorubicin (Sigma, St. Louis, MO), 5-FU
(Sigma, St. Louis, MO) and cisplatin (ALEXIS Biochem-
ical, Lausen Switzerland) for 24, 48 h or 72 h. After
treatments, 20 uL of 5 mg/mL MTT in PBS were added
to each well and incubated for 4 h, and then 100 μL of
lysis buffer was added. The lysis buffer consisted of 20 %
SDS and 50 % dimethyl formamide [11]. The optical
density (O.D.) at 570 nm was determined using a 96-
well plate reader. The viability rates were calculated
from the O.D. readings with various concentrations of
chemotherapeutic agents using the control cells as
100 %.
Western blotting
Same as MTT assay, cells were assigned to three groups
and treated with three different chemoagents. After
treatments, cells were washed twice with cold PBS and
harvested on ice in lysis buffer containing 150 mM
NaCl, 50 mM Tris/HCl (pH 7.6), 1 % Triton, 1 μg/ml
aprotinin, and 100 μg/ml phenylmethylsulfonyl fluoride.
The equivalent volume of loading buffer (100 mM Tris/
HCl (pH 6.8), 4 % SDS, 20 % glycerin, 10 % β-
mercaptoethanol and 0.2 % bromphenol blue) was added
and mixed again. The samples were then denatured at
95 °C for 5 min. After electrophoresis, proteins were
transferred to a polyvinylidene fluoride membrane. The
membrane was probed with rabbit polyclonal antibodies
or mouse monoclonal antibodies against Bcl-2 and
caspase-3 (p34) (Santa Cruz; 1:1000 dilution), EpCAM
(323/A3, Santa Cruz; 1:1000 dilution), or mouse mono-
clonal anti-β-Actin (Sigma 1:5000 dilution) at 4 °C
overnight. After washing, the second antibody (goat
anti-rabbit HRP) and donkey anti-mouse HRP (Santa
Cruz; 1:2500 dilution) were added respectively. Specific
antibody–antigen complexes were detected by using the
ECL Western blot detection kit (Pierce). The protein
bands were quantified by densitometry analysis.
Real-Time RT-PCR (qPCR)
Cells were assigned to three groups and treated with
three different chemoagents. After treatment, total RNA
was extracted using the TRIzol reagent (Invitrogen).
First-strand complimentary DNA (cDNA) was synthe-
sized from total RNA according to the manufacturer’s
protocol for the RNA PCR kit (Promega, Madison, WI,
USA). Quantitative PCR was carried out using the ABI
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7300 real-time PCR system (Applied Biosystems, Carls-
bad, CA). EpCAM expression was quantified and β-actin
was used as an endogenous reference. Results were
expressed as fold change in gene expression.
Flow cytometry analysis
FTIC-conjugated EpCAM monoclonal antibody (EBA-1)
was purchased from Santa Cruz Company. HepG2,
Hep3B and HuH-7 cells were seeded in 6-well plates, in-
cubated at least for 24 h, and reached above 80 % conflu-
ence before chemotherapeutic agent treatment. Different
concentration of doxorubicin, 5-FU and cisplatin were
added to the cells and incubated for 2 days. Finally, cells
were dissociated with 0.25 % trypsin-EDTA (1 mM) (Invi-
trogen) for 3 min and washed with fluorescence-activated
cell sorting buffer (PBS containing 1 % fetal calf serum)
and then incubated for 1 h at 4 °C in fluorescence-
activated cell sorting buffer with the corresponding mAb:
anti-EpCAM. Flow cytometry analysis was performed with
a BD FACSCanto II flow cytometer (BD Biosciences).
Xenograft mice model
Eight-weeks-old nude BALB/c mice were used for the
xenograft model, and six mice were assigned to doxo-
rubicin pretreated Hep3B group and six mice were
assigned to untreated control group. Both FGF21KO
and C57 BL/6 J mice were housed four per cage,
given commercial chow and tap water, and main-
tained at 22 °C on a 12-hour light/dark cycle. To es-
tablish xenograft mice model, Hep3B cells were
cultured in 75 cm2 flasks and pretreated with doxo-
rubicin at 0.5 μM for 24 h. After treatment, the cells
were counted, and 1 million cells were used for in-
oculation and 1 million cells were used for Western
blot to determine the EpCAM protein levels. Doxo-
rubicin pretreated as well as untreated Hep3B cells
were inoculated at 106 cells/mouse into the right
flank for 4 weeks. Betadine solution swabstick will be
used prior to the inoculation. Operation manipula-
tions will be done under sterile conditions. To deter-
mine the tumor size, the length and width of tumor
were measured with an accuracy of 0.01 mm using a
digital caliber. Animal procedures were approved by
the Institutional Animal Care and Use Committee of
University of Louisville, which is certified by the
American Association for Accreditation of Laboratory
Animal Care.
RNA interference
To define the link between chemotherapeutic agents and
EpCAM, a small interfering RNA (siRNA) specific to
TACSTD1 (SI03019667) and a negative control siRNA
(1022076) were designed and synthesized by Qiagen
(Qiagen, Valencia, CA). HepG2 cells were cultured for
overnight at 4 × 105 cells per well in a 6-well plate and
1 × 104 cells per well in 96-well plates. Transfection was
performed using Lipofectamine 2000 transfection re-
agent (Invitrogen), according to the instructions of the
manufacturer. A total of 100 pmol/well of siRNA was
used for 6-well plate transfection, and 5 pmol/well of
siRNA for 96-well plate. After an 8-hour transfection
period, it was changed into fresh medium. After 2-day
incubation, cells were assigned to three groups and
treated with three different concentrations of doxorubi-
cin for another 2 days. Cells in 6-well plates were col-
lected for Western blot analysis. Cells in 96-well plates
received an additional 20 ul of MTT per well for cell via-
bility analysis.
Clinical rationale: chemotherapeutic choices
Doxorubicin, 5-FU, and cisplatin are agents typically
chosen for the treatment of HCC. Specific concentra-
tions of these drugs were chosen based on extrapolations
from two main factors: clinically applicable dosing com-
bined with known pharmacokinetic data (Schaaf [12],
Greene [13], DeJongh [14]). The clinical dosing of these
drugs is based on total body surface area, which is vari-
able for each patient. For that reason, the dosage of
these drugs was standardized based on an average pa-
tient size of 1.25 m2. We chose a value for each drug
that was the approximate median of the range seen in
multiple dosing protocols. By multiplying the dose and
our standardized size, we were able to determine the
number of milligrams administered to the standardized
patient. This mg dosage combined with the volume of
distribution available free therapeutic agent to create a
theoretical chemotherapeutic concentration available in
total body water. This concentration was subsequently
divided by five to account for the presence of the drug
in the extra-cellular fluid alone, as that would be the ac-
tual amount present in contact with tumor cells.
Statistics
All experiments were independently performed, at least,
three times to meet the assumptions of the statistical ap-
proach. The data are expressed as mean ± standard devi-
ation (n = 3–6). The data were analyzed by analysis of
variance (ANOVA) and Newman-Keuls’ Multiple-
Comparison Test. Differences between groups were con-
sidered significant at P <0.05.
Results
Three hepatocellular carcinoma cell lines have different
sensitivity to chemotherapeutic agents
For each carcinoma cell line investigated in this study,
cell viability assays were performed in order to deter-
mine their sensitivities to three chemotherapeutic
agents: doxorubicin, 5-FU and cisplatin. The results
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indicated that all three HCC cells were sensitive to
doxorubicin at lower concentrations, 0.5 and 1 μM. For
2-day exposure to 0.5 μM of doxorubicin, the cell via-
bility of the Hep3B cell line is 58.56 %, HepG2 is
74.52 %, and HuH-7 is 87.84 %. When treated at the
concentration of 4 μM doxorubicin for 3-day treat-
ment, Hep3B were totally dead. However, HepG2 had
6.01 % of cells alive, and HuH-7 had 17.67 % of cells
alive. Based on these results, the Hep3B cells are
more sensitive in vitro to doxorubicin than HepG2
and HuH-7(Fig. 1a). In 5-FU treatment (Fig. 1b), the
HepG2 cells show decreased viability with 5-FU treat-
ment starting at 4 μM, but not Hep3B and HuH-7
cells. Hep3B and HuH-7 cells show decreased viability
with 5-FU treatment starting at 37.5 μM. Cell viability
was also determined in three HCC cell lines after ex-
posure to cisplatin (Fig. 1c). HepG2 cells show de-
creased viability with cisplatin treatment starting at
10 μM. But Hep3B and HuH-7 cells show more re-
sistant to cisplatin. Hep3B and HuH-7 cells show de-
creased viability with cisplatin treatment starting at
80 μM. Depending on cell-line sensitivity to the three
chemotherapeutic agents, the dose is selected to treat
the cells for the EpCAM expression assay.
Doxorubicin exposure decreased EpCAM mRNA level,
protein level and positive cells in HCC cell lines
First, the baseline of EpCAM expressions was evalu-
ated at protein level. The result indicated that Hep3B
cells and HepG2 cells expressed higher level of
EpCAM, while the HuH-7 expressed lower level of
EpCAM (Fig. 2a). When the three HCC cell lines
challenged with chemotherapeutic doxorubicin at sen-
sitive dosing of 0.5 and 1 μM which were determined
previously, there were significant changes in EpCAM
expression at both mRNA and protein levels. The re-
sults indicated that the EpCAM expression was sig-
nificantly down-regulated by doxorubicin treatment in
all three cell lines (Fig. 2b). Interestingly, the higher
baseline levels of EpCAM in both Hep3B and HepG2
cells were significantly decreased by doxorubicin, and
the decreases of EpCAM expressions were associated
to the decreased cell viability. Flow cytometry assay
was performed to further determine whether the
Fig. 1 Three hepatocellular carcinoma cell lines had different sensitivity to chemotherapeutic agents. The blank controls for every different
concentration of chemotherapeutic agents were set up in order to reduce the influence of the chemotherapeutic reagent on MTT results. Dox:
doxorubicin; 5-FU: 5- fluorouracil
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decreased EpCAM expression was associated with de-
creased number of EpCAM positive cells. In the base-
line, the HepG2 cells had 54.5 % of EpCAM positive
cells, the Hep3B cells had 85.9 % of EpCAM positive
cells, and the HuH-7 cells had 41.4 % of EpCAM
positive cells (Fig. 3). This Flow cytometry result of
EpCAM positive cells was consistent to the Western
blot result of EpCAM protein level.
Decreased EpCAM by doxorubicin slowed done the tumor
growth in vivo
To determine whether decreased EpCAM in HCC
cells would affect the tumor growth in vivo, we used
Hep3B cells which were sensitive to doxorubicin for
the xenograft study. The results indicated that doxo-
rubicin pretreated Hep3B cells lost about 40 %
EpCAM protein (Fig. 4a). The loss of EpCAM caused
decrease of the Hep3B cell growth in vivo. As shown
in Fig. 4b, the tumor sizes were significantly de-
creased in doxorubicin pretreated group compared to
untreated group (p <0.05).
Chemo-resistence is positively related to EpCAM
expression in HCC cell lines
As shown in Fig. 1, three HCC cell line, especially
Hep3B and HuH-7, cells showed more resistant to 5-FU
and cisplatin than doxorubicin. Therefore, we further
evaluated the protein levels of EpCAM in three HCC
cells challenged by 5-FU and cisplatin in Hep3B and
HuH-7 cells. The result indicated that show the EpCAM
protein levels of HepG2 cells decreased by both 5-FU
and cisplatin at lower concentrations (5-FU: 75–300 μM;
cisplatin: 40–160 μM). However, the EpCAM protein
levels in Hep3B cells were increased after the challenges
of 5-FU and cisplatin even at higher concentrations (5-
FU: 300–1200 μM; cisplatin: 160–320 μM). Although
the HuH-7 cells showed decreased EpCAM protein
levels when treated with 5-FU at concentration of
300 μM, the decreases became blunt when treated at
higher concentrations from 600 to 2400 μM. For the
treatment of cisplatin, HuH-7 cells showed decreased
EpCAM protein level when treated at concentration of
80 μM, however EpCAM protein levels were increased
when treated with cisplatin at higher concentration from
Fig. 2 EpCAM protein expression level was decreased by doxorubicin in HCC cell lines. a Baseline EpCAM protein levels in HepG2 cells,
Hep3B cells and HuH-7cells. The bands were scanned and analyzed with ImageQuant 5.2 software. The quantification was presented as
Pixel ratio. b EpCAM mRNA and protein levels in HepG2 cells, Hep3B cells and HuH-7cells challenged by doxorubicin. Data are presented
as mean ± SD. *p <0.05 vs control; **p <0.01 vs control
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160 to 640 μM (Fig. 5). Unlike doxorubicin, 5-FU and
cisplatin challenged HCC cells showed a different
EpCAM expression pattern, and this discrepancy im-
plied that doxorubicin could target directly to EpCAM
but not 5-FU and cisplatin.
EpCAM knock-down attenuated cell mortality after
doxorubicin exposure
To investigate if EpCAM is a target of doxorubicin,
EpCAM siRNA was transfected into HepG2 cells. We se-
lected the HepG2 cells based on the previous finding of
the doxorubicin sensitivity in Fig. 1. With doxorubicin
challenge, the viability of HepG2 cell (74.52 %) was either
not too high or too low, in the middle between Hep3B cell
(58.56 %) and HuH-7 (87.84 %). Therefore, use of HepG2
cell can avoid the experimental bias. After a 2-days
incubation of EpCAM siRNA, HepG2 cells were treated
with doxorubicin, at 0.5, 1 and 2 μM for an additional
2 days. In the no-doxorubicin treatment group, we modi-
fied 100 % of cell proliferation as control group. MTT
assay showed the cell viabilities were significantly in-
creased (P <0.05 or P <0.01, vs negative control) in all
EpCAM siRNA groups after doxorubicin treatment
(Fig. 6a).
As we know that apoptosis is an important mechanism
for doxorubicin induced cell death, we further investigated
two important effectors of cell apoptosis, Bcl-2 and
Caspase-3 (p34). Bcl-2 is an anti-apoptosis protein related
to cell proliferation and cell survival. Cell viability is partly
recovered if Bcl-2 is increased. Caspase-3 (p34) is
expressed in cells as an inactive precursor from which the
p17 and p11 subunits of the mature caspase-3 are proteo-
lytically generated during apoptosis. Western blotting re-
sults showed that EpCAM protein levels were significantly
decreased in the HepG2 cells compared to that in negative
transfection control and non-transfection control (P
<0.01). When the HepG2 cells with EpCAM siRNA trans-
fection challenged by doxorubicin, the EpCAM protein
level was further decreased (P <0.05). Bcl-2 was decreased
when the cells challenged by doxorubicin, but the Bcl-2
protein was in a higher level when EpCAM being silenced
compared to that in non-transfection control and negative
transfection control (P 0.01). Similar to Bcl-2, the inactive
form of caspase-3 (p34) was decreased when the non-
Fig. 3 Flow cytometry analysis of EpCAM positive cells. In the baseline, Hep3B cells have a much higher percentage of EpCAM positive cells than
HepG2 and HuH-7. Doxorubicin exposure decreased EpCAM positive cell percentages in HepG2, Hep3B and HuH-7 cells
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transfection control cells and negative transfection control
cells challenged by doxorubicin. However EpCAM si-
lenced HepG2 cells maintained a higher protein level of
caspase-3 (p34), indicating that less apoptotic effectors
(caspase-3 p17 and caspase-3 p11) was proteolytically gen-
erated (Fig. 6b). This showed that EpCAM knock-down
made doxorubicin lose its cell-killing target.
Discussion
In the present study, we found that doxorubicin could
decrease EpCAM expression level and percentage of
EpCAM positive cell population in HepG2, Hep3B and
HuH-7 cell lines, and with cell viability decreasing. We
used EpCAM siRNA knock-out EpCAM expression in
three cell lines and found cell mortality was attenuated
when cells were exposed to doxorubicin, which suggests
that EpCAM was one of the targets of doxorubicin.
We first compared the viability of three cell lines,
HepG2, Hep3B and HuH-7, exposed to chemotherapeu-
tic agents. We found that in different cell lines, there are
different levels of sensitivity to doxorubicin, 5-FU and
cisplatin. Hep3B is more sensitive to doxorubicin than
HepG2 and HuH-7. HepG2 is more sensitive to 5-FU
and cisplatin than Hep3B and HuH-7. This is an insight
to clinic for chemotherapy.
Epithelial Cellular Adhesion Molecule (EpCAM), also
known as KS1/4, gp40, GA733-2, 17-1A, and TROP-1, is
a transmembrane glycoprotein that functions as a homo-
philic Ca2+−independent adhesion molecule. EpCAM is
a pan-epithelial differentiation carcinoma-associated
Fig. 4 Decreased EpCAM by doxorubicin slowed done the tumor growth in vivo. a EpCAM expression was decreased in Hep3B cells after doxorubicin
treatment at 0.5 μM for 24 h. b Doxorubicin pretreatment significantly deceased tumor size in vivo compared to untreated group. Data are presented
as mean ± SD. *p <0.05 vs untreated Hep3B inoculation group
Fig. 5 Chemo-resistence is positively related to EpCAM expression in HCC cell lines after 5-FU and cisplatin treatment. EpCAM protein levels were
analyzed by Western blot. The bands were scanned and analyzed with ImageQuant 5.2 software. The optical density was modified one as control
group. Data are presented as mean ± SD. *p <0.05 vs control; **p <0.01 vs control. Each experiment was repeated times times
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antigen expressed on almost all carcinomas. EpCAM is
up-regulated in the majority of human epithelial carcin-
omas, including colorectal [15], breast [16, 17], prostate
[18], lung [19], cervical epithelium [20, 21], colon, head
and neck [22], and hepatic carcinomas [23, 24]. The
expression levels of EpCAM correlate with de-
differentiation and malignant proliferation of epithelial
cells. The level of EpCAM expression and the number
of positive cells has been found to increase with the
grade of carcinogenesis in cervical intraepithelial neopla-
sia [20]. Increasing amounts of EpCAM also has been
correlated with lower life expectancy of lung cancer pa-
tients [19]. EpCAM is highly over-expressed in primary
and metastatic breast cancer and associated with poor
disease-free and overall survival in primary breast can-
cers [25].
EpCAM directly impacts cell cycle, proliferation,
and metabolism and induces the protooncogene c-
myc and the cell cycle regulating genes cyclinA and E
[26]. Inhibition of EpCAM expression has been
shown to result in a dramatic change in phenotype
and a decreased proliferation of carcinoma cells [23].
Silencing of EpCAM expression decreased the migra-
tion rate [27]. EpCAM and Wnt-β-catenin act in the
same signaling pathway [28].
EpCAM is used as a cancer stem cell marker [27], and
as an early biomarker of hepatocellular carcinoma [29].
EpCAM is also a biomarker for hepatic stem cells
[30–32]. In addition, several clinical trials targeting
EpCAM have been conducted [33].
The majority of hepatocytes in 8-week embryonic liver
showed EpCAM expression [24]. Abnormal liver tissue
displayed a strong EpCAM expression in the epithelium
of typical and atypical bile ducts. In addition, periportal
or periseptal hepatocytes revealed variable staining of
EpCAM, which is directly related to acute and chronic
inflammatory changes. The EpCAM expression in hepa-
tocytes was most pronounced in acute and chronic ac-
tive hepatitis, with EpCAM expression levels that are
common to bile ductular cells. This suggests that the
hepatocytes in diseased liver represent transformed
hepatocytes.
It is known that mature hepatocytes are negative
for EpCAM expression. EpCAM-positive HCC dis-
plays a distinct molecular signature with features of
hepatic progenitor cells. Wnt-β-catenin signaling plays
a pivotal role in embryogenesis and the maintenance
of stem cell growth [34] and is activated during liver
development/regeneration [35, 36]. EpCAM and
Wnt–β-catenin signaling are connected, and both play
a role in the maintenance of hepatic cancer stem cells
[37]. EpCAM is one of the direct transcriptional tar-
gets of Wnt-β-catenin signaling in normal human he-
patocytes and HCC cell lines [28].
Fig. 6 EpCAM knock-down attenuated cell mortality after doxorubicin exposure. a cell viability by MTT assay. b the protein levels of EpCAM, Bcl-2
and Caspase-3 (p34) by Western blot. NC negative transfection control, Dox doxorubicin. Data are presented as mean ± SD. *p <0.05 vs NC (Top);
**p <0.01 vs NC (Top). Each experiment was repeated 3 times
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We used three human cell lines. HepG2 cells were iso-
lated from a15-year-old Caucasian, this cell line contains
the wild-type TP53 gene. There is no evidence of a hepa-
titis B virus genome in this cell line. Hep3B cells were
isolated from an 8-year-old black juvenile. This cell line
contains an integrated hepatitis B virus genome and has
lost the TP53 gene. HuH-7 cells were isolated from a
57-year-old Japanese, without HBV, and partly TP53-
gene mutated [38]. p53 is a tumor suppressor protein
that in humans is encoded by the TP53 gene. It plays an
important role in apoptosis, genetic stability, and inhib-
ition of angiogenesis in multicellular organisms. It regu-
lates the cell cycle and, thus, functions as a tumor
suppressor that is involved in preventing cancer. It can
activate DNA repair proteins when DNA has sustained
damage; induce growth arrest by holding the cell cycle
at the G1/S regulation point on DNA damage recogni-
tion; and initiate apoptosis if DNA damage proves to be
irreparable. It is reported that wild-type p53 negatively
regulates EpCAM expression [39]. In patients with
chronic hepatitis B, EpCAM is up-regulated [40]. In
these studies, our flow cytometry assays show that the
Hep3B cell line is almost 90 % EpCAM positive expres-
sion; however HepG2 is about 50 % EpCAM positive
and HuH-7 is about 45 % EpCAM positive. Since there
are different baseline EpCAM positive cell levels in the
three cell lines, the higher the level of positive EpCAM
cells, the more sensitive to doxorubicin. Our results
showed that Hep3B is more sensitive to doxorubicin
than HepG2 and HuH-7. Because EpCAM is oncogene
[26, 41], our in vitro data suggest that, in this way, doxo-
rubicin is better than 5-FU and cisplatin for HCC.
Conclusion
Chemotherapeutic agent resistance is the main obstacle
to successful liver cancer treatment. Chemotherapeutic
drugs kill cancer cells through apoptosis [42]. EpCAM is
a biomarker of cancer stem cells, has the ability to re-
constitute tumors, and is involved in tumor resistance to
chemo/radiation therapy. Those characteristics help
show the role of EpCAM in tumor relapse and progres-
sion. At one time, we thought EpCAM had a relation-
ship with chemotherapeutic agent assistance [43]. In our
experiment we actually found that EpCAM was up-
regulated with the chemotherapeutic agent killing the
cells in some cell lines. We may think that EpCAM has
a role in cell survival. This is worth investigating it in
the future study.
Abbreviations
5-FU: 5- fluorouracil, a chemotherapeutic agent; dTMP: deoxythymidylate;
EpCAM: epithelial cell adhesion molecule (EpCAM; HCC: hepatocellular
carcinoma; Hep3B: hepatocellular carcinoma cell line; HepG2: hepatocellular
carcinoma cell line; HuH-7: hepatocellular carcinoma cell line; siRNA: small
interfering RNA.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors YL, RWF, YY, RCGM made substantial contributions to conception,
design, analysis, and interpretation of data. YL, RWF, YY and RCGM each
contributed to the experimental design, authorship, and research within the
existing literature for this article. YL directed the work in the lab, and RWF,
YL, and RCGM reviewed and interpreted results of the laboratory assays. All
authors have read and approved the manuscript.
Acknowledgment
This work was supported in part by American Diabetes Association Basic
Science Award (1-13-BS-109).
Author details
1Division of Surgical Oncology, University of Louisville School of Medicine,
Louisville, KY 40202, USA. 2School of Life Science, Southwest University,
Chongqing 400716, China. 3Department of Surgery, Division of Surgical
Oncology, University of Louisville School of Medicine, 315 E. Broadway -
#312, Louisville, KY 40202, USA.
Received: 8 September 2015 Accepted: 8 March 2016
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55:74–108.
2. Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist.
2005;10:269–81.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes
to environment. Nat Rev Cancer. 2006;6:674–87.
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action
and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.
5. Fang F, Hoskins J, Butler JS. 5-fluorouracil enhances exosome-dependent
accumulation of polyadenylated rRNAs. Mol Cell Biol. 2004;24:10766–76.
6. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by
doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol
Pharmacol. 1994;45:649–56.
7. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA,
RNA, and protein synthesis in cell-free systems and intact cells. Cancer
Res. 1976;36:2891–5.
8. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-
CAM expression is associated with poor prognosis in node-positive breast
cancer. Breast Cancer Res Treat. 2004;86:207–13.
9. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, et al.
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an
independent prognostic marker for reduced survival of patients with
epithelial ovarian cancer. Gynecol Oncol. 2006;103:483–8.
10. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A,
Verde PE, et al. Ep-CAM expression in squamous cell carcinoma of the
esophagus: a potential therapeutic target and prognostic marker. BMC
Cancer. 2006;6:165.
11. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of
a precise and rapid dye method for measuring cell growth/cell kill. J
Immunol Methods. 1989;119:203–10.
12. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population
pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother
Pharmacol. 2004;54:105–12.
13. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma
pharmacokinetics of adriamycin and adriamycinol: implications for the
design of in vitro experiments and treatment protocols. Cancer Res. 1983;
43:3417–21.
14. Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG. Nonlinear pharmacokinetic
characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. 1987.
p. 411–8.
15. Packeisen J, Kaup-Franzen C, Knieriem HJ. Detection of surface antigen 17-
1A in breast and colorectal cancer. Hybridoma. 1999;18:37–40.
16. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell
adhesion molecule (EpCAM) is overexpressed in breast cancer metastases.
Breast Cancer Res Treat. 2010;123:701–8.
Li et al. BMC Cancer  (2016) 16:228 Page 9 of 10
17. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ,
Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential
target for breast cancer gene therapy. Cancer Res. 2004;64:5818–24.
18. Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS,
Player A, Kawasaki ES. Identification of EpCAM as a molecular target of
prostate cancer stroma. Am J Pathol. 2009;175:2277–87.
19. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE. The
expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum
Pathol. 2000;31:482–7.
20. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren
GJ, et al. Expression of Ep-CAM in cervical squamous epithelia correlates
with an increased proliferation and the disappearance of markers for
terminal differentiation. Am J Pathol. 1996;148:865–75.
21. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO,
Fleuren GJ, et al. Changing roles of cadherins and catenins during
progression of squamous intraepithelial lesions in the uterine cervix. Am J
Pathol. 1999;155:505–15.
22. Pauli C, Munz M, Kieu C, Mack B, Breinl P, Wollenberg B, et al. Tumor-
specific glycosylation of the carcinoma-associated epithelial cell adhesion
molecule EpCAM in head and neck carcinomas. Cancer Lett. 2003;93:25–32.
23. Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, et al. Characterization
of the epithelial cell adhesion molecule (EpCAM)+ cell population in
hepatocellular carcinoma cell lines. Cancer Sci. 2010;101:2145–55.
24. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of
Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol.
1999;188:201–6.
25. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in
breast cancer as a predictor of survival. Lancet. 2000;356:1981–2.
26. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-
associated antigen EpCAM upregulates c-myc and induces cell proliferation.
Oncogene. 2004;23:5748–58.
27. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-
positive hepatocellular carcinoma cells are tumor-initiating cells with stem/
progenitor cell features. Gastroenterology. 2009;136:1012–24.
28. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell
marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
Cancer Res. 2007;67:10831–9.
29. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma:
conventional and molecular diagnosis. Semin Liver Dis. 2010;30:17–25.
30. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human
hepatic progenitors. Stem Cells. 2006;24:1852–8.
31. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, et al. Human
hepatic stem cells from fetal and postnatal donors. J Exp Med. 2007;204:1973–87.
32. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, et al. Isolation of
multipotent progenitor cells from human fetal liver capable of
differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S
A. 2006;103:9912–7.
33. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer.
2007;96:417–23.
34. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:
843–50.
35. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, Monga SP. Beta-
catenin is temporally regulated during normal liver development.
Gastroenterology. 2004;126:1134–46.
36. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. Beta-
catenin antisense studies in embryonic liver cultures: role in proliferation,
apoptosis, and lineage specification. Gastroenterology. 2003;124:202–16.
37. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/beta-catenin
signaling contributes to activation of normal and tumorigenic liver
progenitor cells. Cancer Res. 2008;68:4287–95.
38. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. p53 gene
mutation and integrated hepatitis B viral DNA sequences in human liver
cancer cell lines. Carcinogenesis. 1993;14:987–92.
39. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE.
Transcriptional repression of epithelial cell adhesion molecule contributes to
p53 control of breast cancer invasion. Cancer Res. 2009;69:753–7.
40. Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S. Intrahepatic
gene expression profiles in chronic hepatitis B and autoimmune liver
disease. J Gastroenterol. 2008;43:866–74.
41. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling
by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11:162–71.
42. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer
genetics and chemotherapy. Cell. 2002;108:153–64.
43. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, et al.
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance
to interferon-alpha/5-fluorouracil combination therapy for hepatocellular
carcinoma. Br J Cancer. 2009;100:1647–58.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. BMC Cancer  (2016) 16:228 Page 10 of 10
